Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
December 13, 2021 5:00 PM ESTKENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has placed clinical holds on the investigational new drug applications (INDs) for the oral and implant formulations of islatravir (MK-8591) for HIV-1 pre-exposure prophylaxis (PrEP); the injectable formulation of islatravir for HIV-1 treatment and prophylaxis; and the oral doravirine/islatravir (DOR/ISL) HIV-1 once-daily treatment. The FDAs clinical hold is based on previously announced observations of decreases in total lymphocyte and CD4+ T-cell counts in... More
